EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal stability of progression‐related microglial activity during teriflunomide treatment in patients with multiple sclerosis

Jussi Lehto iD, Marjo Nylund, Markus Matilainen, Marcus Sucksdorff, Anna Vuorimaa, Johan Rajander, Saara Wahlroos, Parisa Hariri, Laura Airas

European Journal of Neurology · 2023

DOI: 10.1111/ene.15834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Jussi Lehto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Turku PET Centre, Turku, Finland. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, White Matter. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, European Committee for Treatment and Research in Multiple Sclerosis, Sanofi Genzyme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose The aim was to study brain innate immune cell activation in teriflunomide‐treated patients with relapsing–remitting multiple sclerosis.

Methods

Imaging with 18‐kDa translocator protein positron emission tomography (TSPO‐PET) using the [ 11 C]PK11195 radioligand was employed to assess microglial activity in the white matter, thalamus and areas surrounding chronic white matter lesions in 12 patients with relapsing–remitting multiple sclerosis who had been treated with teriflunomide for at least 6 months before inclusion. Magnetic resonance imaging (MRI) was used to measure lesion load and brain volume, and quantitative susceptibility mapping (QSM) was used to detect iron rim lesions. These evaluations were repeated after 1 year of inclusion. Twelve age‐ and gender‐matched healthy control subjects were imaged for comparison.

Results

Half of the patients had iron rim lesions. In TSPO‐PET, the proportion of active voxels indicating innate immune cell activation was slightly greater amongst patients compared with healthy individuals (7.7% vs. 5.4%, p = 0.033). The mean distribution volume ratio of [ 11 C]PK11195 was not significantly different in the normal‐appearing white matter or thalamus amongst patients versus controls. Amongst the treated patients, no significant alteration was observed in positron emission tomography distribution volume ratio, the proportion of active voxels, the number of iron‐rim‐positive lesions, lesion load or brain volume during follow‐up.

Conclusions

Compared to controls, treated patients exhibited modest signs of diffuse innate immune cell activity, which was unaltered during follow‐up. Lesion‐associated smoldering inflammation was negligible at both timepoints. To our knowledge, this is the first study applying both TSPO‐PET and QSM‐MRI to longitudinally evaluate smoldering inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingWhite MatterHumansMicrogliaBrainMagnetic Resonance ImagingInflammationIronReceptors, GABACrotonatesHydroxybutyratesNitrilesToluidines

Stichwörter der Autor:innen

magnetic resonance imagingmultiple sclerosispositron emission tomographyquantitative susceptibility mappingteriflunomide

Substanzen

IronReceptors, GABAteriflunomideCrotonatesHydroxybutyratesNitrilesToluidinesTSPO protein, human

Autor:innen und Institutionen

  • Turku PET Centre, Turku, Finland.
  • Neurocenter, Turku University Hospital, Turku, Finland.
  • Clinical Neurosciences, University of Turku, Turku, Finland.
  • Åbo Akademi University, Turku, Finland.

ORCID-Profile: Jussi Lehto

Förderung

  • Academy of Finland
  • European Committee for Treatment and Research in Multiple Sclerosis
  • Sanofi Genzyme
  • Sigrid Juséliuksen Säätiö

Zitieren

APA

Lehto, J., Nylund, M., Matilainen, M., Sucksdorff, M., Vuorimaa, A., Rajander, J., Wahlroos, S., Hariri, P., & Airas, L. (2023). Longitudinal stability of progression‐related microglial activity during teriflunomide treatment in patients with multiple sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.15834

Vancouver

Lehto J, Nylund M, Matilainen M, Sucksdorff M, Vuorimaa A, Rajander J, et al. Longitudinal stability of progression‐related microglial activity during teriflunomide treatment in patients with multiple sclerosis. European Journal of Neurology. 2023. doi:10.1111/ene.15834

BibTeX
@article{Lehto2023,
  author = {Lehto, Jussi and Nylund, Marjo and Matilainen, Markus and Sucksdorff, Marcus and Vuorimaa, Anna and Rajander, Johan and Wahlroos, Saara and Hariri, Parisa and Airas, Laura},
  title = {Longitudinal stability of progression‐related microglial activity during teriflunomide treatment in patients with multiple sclerosis},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15834}
}
Kostenlos starten →